CBA Florida (OTCMKTS:CBAI) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
15.2% of Celcuity shares are owned by institutional investors. 30.0% of CBA Florida shares are owned by insiders. Comparatively, 43.5% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
CBA Florida has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Earnings and Valuation
This table compares CBA Florida and Celcuity’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
This is a summary of recent recommendations and price targets for CBA Florida and Celcuity, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity has a consensus target price of $35.50, suggesting a potential upside of 53.81%. Given Celcuity’s higher possible upside, analysts plainly believe Celcuity is more favorable than CBA Florida.
This table compares CBA Florida and Celcuity’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Celcuity beats CBA Florida on 5 of the 8 factors compared between the two stocks.
About CBA Florida
CBA Florida, Inc. does not have significant operations. Previously, the company provided umbilical cord blood and cord tissue stem cell processing and storage to families in the United States. The company was formerly known as Cord Blood America, Inc. and changed its name to CBA Florida, Inc. in May 2018. CBA Florida, Inc. is headquartered in Las Vegas, Nevada.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for CBA Florida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CBA Florida and related companies with MarketBeat.com's FREE daily email newsletter.